Glaxo: Study of Shingles Vaccine Meets Primary Objective
18 December 2014 - 11:52PM
Dow Jones News
By Tapan Panchal
LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday that a phase
III study to assess the efficacy of an investigational vaccine for
the prevention of shingles has met its primary objective.
Analysis showed that the HZ/su vaccine reduced the risk of
shingles by 97.2% in adults aged 50 years and older, compared with
placebo.
Shingles is a type of rash that develops on one side of the
human body caused by the chickenpox virus.
At 1209 GMT, shares of Glaxo were trading 0.5% higher at 1,354
pence.
-Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024